On Wednesday, BMO Capital Markets adjusted its outlook on shares of Bayer AG (ETR:BAYGN) (BAYN:GR) (OTC: BAYRY), reducing the price target from €30.00 to €26.00 while maintaining a Market Perform rating.
The revision follows Bayer (OTC:BAYRY)'s third-quarter performance, which did not meet expectations, and the company's subsequent reduction in its 2024 financial guidance. Moreover, Bayer's initial 2025 projections failed to impress, adding to the analysts' concerns.
Bayer's Crop Science division is expected to see weaker performance than its competitors, who have been projecting double-digit year-over-year growth. In contrast, Bayer anticipates a contraction in this area. Furthermore, the pharmaceutical segment of the company is also expected to experience a more significant earnings contraction than previously estimated by BMO Capital.
Despite these setbacks, Bayer's valuation remains seemingly attractive. However, the ongoing earnings contraction and the unresolved issues surrounding glyphosate litigation have prompted BMO Capital to maintain a neutral stance on the stock. The analyst's comments highlight these challenges and the reasoning behind the lowered price target.
The new price target of €26.00 is based on approximately 6.5 to 7 times the estimated 2025 enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio. This figure represents a discount to BMO Capital's estimated sum-of-the-parts (SOTP) valuation of €30.00 per share for the year 2025. The adjustment reflects the analyst's recalibrated expectations for Bayer's financial trajectory over the next few years.
In other recent news, Bayer AG has been making notable strides. The company secured a significant legal victory when a Philadelphia Court jury ruled in favor of Bayer's Monsanto (NYSE:MON) unit in the Young Roundup product liability trial.
This outcome marks a crucial development in Bayer's ongoing legal challenges concerning allegations that Monsanto's Roundup weed killer causes cancer. The verdict could potentially influence the trajectory of future litigation involving Bayer and its widely used herbicide.
In another development, BofA Securities upgraded its rating on Bayer's stock from Underperform to Neutral, while also raising the price target from EUR27.00 to EUR31.00. This shift was influenced by a more optimistic outlook on the resolution of Bayer's legal issues, specifically those related to glyphosate and PCB.
BofA Securities' revised price target also incorporates a change in the projected price-to-earnings ratio for the fiscal year 2025, from 5.5 times to 6 times. These recent developments underscore Bayer's progress in addressing ongoing litigation concerns and adjusting its future earnings valuation.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Bayer's current financial situation, complementing BMO Capital's analysis. Despite the challenges highlighted in the article, Bayer's Price to Book ratio stands at a low 0.57, suggesting the stock might be undervalued relative to its assets. This aligns with the article's mention of Bayer's seemingly attractive valuation.
InvestingPro Tips indicate that Bayer has maintained dividend payments for 33 consecutive years, demonstrating a commitment to shareholder returns even in challenging times. However, the stock is currently trading near its 52-week low, reflecting the market's concerns about the company's outlook.
It's worth noting that while Bayer wasn't profitable over the last twelve months, analysts predict the company will return to profitability this year. This forecast could provide some optimism for investors looking beyond the current challenges described in the article.
For readers seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Bayer, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.